A cytotoxic drug against reperfusion injury?

H. Rüdiger,P. Clavien

DOI: https://doi.org/10.1002/hep.510310240

IF: 17.298

2000-02-01

Hepatology

Abstract:Cells primed by various types of stress are known to develop tolerance to subsequent lethal injury. This biological adaptation is the basis of preconditioning. There are many ways to induce preconditioning in vivo, such as short periods of ischemia, increased temperature (heat shock), or the use of pharmacological agents. Preconditioning was first shown to be protective in a whole organ in vivo in a study by Murry et al.1 in which a brief period of cardiac ischemia conferred protection against a subsequent period of prolonged ischemia in dogs. This phenomenon, known as ischemic preconditioning, was subsequently demonstrated in various tissues including skeletal muscle,2 brain,3 spinal cord,4 kidney,5 retina,6 lung,7 intestine,8 and liver.9-11 In the case of liver, Peralta et al.9 have shown that a period of 10 minutes of ischemia followed by 10 minutes of reperfusion protects the liver against subsequent periods of ischemia. The mechanisms by which ischemic preconditioning confers protection to the liver remain largely unknown. Attempts at elucidating underlying mechanisms of preconditioning have incriminated various molecules such as nitric oxide (NO),12 adenosine with its phosphorylated forms,13 protein kinase C,14 catecholamines,15 reactive oxygen species,16 or heat shock proteins.17 A possible mechanism involves the release of adenosine, which rapidly induces NO.9,12 NO triggers various reactions that might have protective effects, including inhibition of endothelin9 and various cytosolic proteases.18,19 Down-regulation of tumor necrosis factor may also occur because tumor necrosis factor released from the Kupffer cells on reperfusion is attenuated by ischemic preconditioning in the rat.20 Apoptosis is a central mechanism of injury in the ischemic liver.21,22 Our group has shown that ischemic preconditioning dramatically reduces apoptosis of the sinusoidal endothelial cells and hepatocytes after reperfusion in the mouse liver.10 We recently performed a prospective pilot study of ischemic preconditioning in 24 patients undergoing hemihepatectomies under exactly 30 minutes of inflow occlusion (Pringle maneuver).11 We found that a period of 10 minutes of ischemia followed by 10 minutes of reperfusion before liver resection was associated with significant reduction in postoperative transaminase levels. This study also provided evidence for sinusoidal endothelial apoptosis in the early stage of reperfusion in humans and suggested protective effects of ischemic preconditioning against this type of injury.11 Over the past 30 years, several investigators have shown that sublethal stress induces a group of ubiquitous proteins in various cell types.23-26 These ‘‘stress proteins,’’ also called heat shock proteins (HSP) because of the initial stressor studied, constitute a heterogeneous group of proteins with diverse protective properties. Among these proteins, the heme oxygenase family (HO) has been receiving increasing attention.17 A central and ubiquitous role of these stress enzymes has been shown in several models of ischemic preconditioning including the liver.27-30 The heme oxygenase system consists of two principal isoforms, the oxidative stress-inducible heme oxygenase 1 (HO-1, HSP32) and the constitutive heme oxygenase-2 (HO-2).17 HO-2 does not belong to the family of heat-shock proteins. Numerous exogenous factors are known to induce HO-1 including heat,17 ischemia,28 hypoxia,28 oxidative stress,17 and glutathione-oxidation (GSH-depletion).17 None of these inducers of HO-1 increase the expression of HO-2.30 The only known inducers of HO-2 are adrenal glucocorticoids.17 Under normal physiological conditions HO-2 is the predominant isoform present in the liver,17,30 and approximately 85% of HO activity is located in hepatocytes.30 After a stress event, the protein levels of HO-1 increase up to 30 times the physiologic levels.30 Although these two HO isoforms differ with respect to regulation, distribution, and chemical structure, they both play a central role in mammalian heme metabolism by catalyzing the cleavage of heme with the concomitant formation of biliverdin,31 carbon monoxide,29 and free iron (Fe12).17 All products of the HO reaction appear to be biologically active.17 Biliverdin is a potent antioxidant.27 Carbon monoxide, like NO, has various signaling functions, e.g., in the generation of cyclic guanylate monophosphate in various biological systems.32 Of note, iron regulates several genes including that of NO synthase (NOS),17 and NOS activity might be a crucial protective mediator in ischemic preconditioning as discussed above.12,33 In addition, HO-activity attenuates the deleterious effects of the heme molecule, which include the formation of oxygen free radicals.17 We are just beginning to understand the complexity and biological importance of the heme oxygenase system, not only as a vital mechanism to maintain the metabolism of the heme molecule but also as a pivotal regulator of the cellular redox state and a source for several signaling molecules. In this issue of HEPATOLOGY, Ito et al.34 used a rat model to investigate the pharmacological activation of the HO system and its role in preventing ischemia and reperfusion injury. They induced HO activity using the anticancer drug, doxorubicin, which induces HO-1 expression in an indirect fashion through generation of oxygen-free radicals.35 The idea of initiating pharmacological preconditioning in the liver using anticancer agents had been introduced by Yamamoto et al.35 Abbreviations: NO, nitric oxide; HSP, heat shock protein; HO, heme oxygenase; NOS, nitric oxide synthase. From the Section of Hepatobiliary Surgery and Transplantation, Department of Surgery, Duke University Medical Center, Durham, NC. Received December 13, 1999; accepted December 14, 1999. Supported by NIH-grant DK54048-01A1 (to P.-A.C.). Address reprint requests to: Pierre-Alain Clavien, M.D., Ph.D., FACS, Professor of Surgery, Duke University Medical Center, P.O. Box 3247, Durham, NC 27710. E-mail: clavi001@mc.duke.edu; fax: 919-681-7508. Copyright r 2000 by the American Association for the Study of Liver Diseases. 0270-9139/00/3102-0041$3.00/0